Background: Neoadjuvant chemotherapy is increasingly applied in patients with locally advanced cancers of many tumour types. Usually three cycles of chemotherapy are administered to reduce the tumour size prior to local therapy, and another three cycles thereafter. The chemotherapy certainly contributes to the improved outcome of this approach. However, biological factors within the primary tumour have been neglected, while they might also contribute to the eradication of micrometastases. We believe that the neoadjuvant strategy can be improved by optimally exploiting certain biological factors inherent to the primary tumour. In a group of patients with locally advanced breast cancer (LABC) we studied this concept. Recently we described the clinical results of this phase II study in patients with LABC treated with neoadjuvant chemotherapy plus granulocyte-macrophage colony-stimulating factor (GM-CSF). A remarkable good response and survival was seen. In contrast to other studies we applied six cycles of neoadjuvant treatment in stead of a sandwich approach consisting
Introduction
Patients with locally advanced cancers have a poor prognosis when treated with surgery and/or radiotherapy alone. This holds for breast cancer, oesophageal cancer, head and neck cancer, stomach cancer and others. Such tumours usually have micrometastases, which grow rapidly following local treatment of the primary tumour and its draining lymph nodes after diagnosis. More recently an approach consisting of three neoadjuvant chemotherapy treatment cycles has been adopted with the main goal to reduce the primary tumour, followed by local treatment and often post-operative chemotherapy. We selected LABC breast cancer as a model to investigate a novel approach.
LABC consists of a heterogeneous group of breast neoplasms with different biological and clinical characteristics. These tumours include stage IIIA and IIIB breast cancer [1] . Patients with LABC have a poor survival when treated by surgery and/or radiotherapy alone [2] . With local therapy alone systemic metastases generally develop rapidly, indicating that most of these patients already have micrometastases at presentation. The fiveyear overall survival (OS) of patients treated with surgery or radiotherapy alone is less than 20%. Since the mid-eighties the management of LABC changed and primary or neoadjuvant chemotherapy became part of the multimodality approach in LABC. Neoadjuvant chemotherapy definitely improves survival in patients with LABC. Patients usually receive three cycles of chemotherapy prior to local therapy often followed by adjuvant chemotherapy.
Recently we have performed a study with four to six neoadjuvant cycles of moderately high-dose doxorubicin (adriamycin®), cyclophosphamide, and GM-CSF (AC + GM-CSF) prior to surgery and postoperative radiotherapy in 42 patients with LABC [3] . We applied moderately high dosages of AC supported by GM-CSF as a haematopoietic growth factor and immuno-stimulatory drug [4, 5] . Initially, some patients were treated with =$4 cycles, but as the study progressed six cycles were given in the majority of cases. Briefly, we observed a high response rate of 98%, no patient showed progressive disease during this approach. Patients who received six cycles of chemotherapy showed a significant improvement in disease-free (DFS) and OS. Three years DFS are 0%, 54% and 70% for respectively four, five and six treatment cycles. The three-year OS are 20%, 77% and 92% for patients who received respectively four, five or six treatment cycles [3] . The results of this study with neoadjuvant AC + GM-CSF compare favourably with previous studies [6] [7] [8] . Dose escalation of cytotoxic drugs may have contributed to some extent to these results although the survival of patients treated in studies with high-dose chemotherapy and stem cell support were not encouraging [9, 10] . Our approach to LABC and more recently also our protocol with oesophageal cancer is different from most studies in two ways. Firstly we apply six cycles (when possible) neoadjuvant in stead of three cycles followed by local therapy and three adjuvant cycles and secondly we apply GM-CSF as a haematopoietic growth factor. Most investigators select G-CSF as a haematopoietic growth factor because of its mild toxicity profile. We opted for GM-CSF because of its immunomodulatory characteristics in addition to its haematopoietic effects.
The encouraging DFS and OS we observed in patients treated with six neoadjuvant treatment cycles triggered translational studies in locally advanced primary tumours in order to investigate two hypotheses as described below.
Immunotherapeutic effect of GM-CSF and prolonged presence of the primary tumour and its draining lymph nodes Recently published vaccination trials have drawn attention to the potential of immunotherapeutic approaches to the treatment of cancer [11] [12] [13] . Most of the more recent immunotherapeutic trials incorporate dendritic cells (DC). DC stem from bone marrow progenitor cells and are the most professional antigen presenting cells [14] [15] [16] . They are optimally equipped to activate naive or memory T cells. Through their powerful T-cell activating machinery they may circumvent immunosuppressive and tolerising conditions often associated with tumours. Several immunogenic antigens are overexpressed in breast tumours (e.g., Her-2/neu, CEA, MUC-1 and Epcam) and may represent suitable targets for tumour-specific cytotoxic T cells (CTL) [17, 18] . Based on the premise that DC can activate these CTL in vivo we aim to optimise the neoadjuvant treatment strategy such as to increase the likelihood of this event occurring. The first hypothesis therefore proposes that the combination of chemotherapy, GM-CSF and long term conservation of primary tumour and tumour-draining lymph nodes leads to the recruitment and improved differentiation of DC and the subsequent activation of tumour-specific CTL. These in turn contributes to the eradication of the primary tumour and micrometastases ( Figure 1 ).
In recent years considerable advances have been made in the understanding of the interplay between tumours and the immune system. New insights suggest several ways in which the followed therapeutic regimen in LABC may facilitate the induction of tumour-specific CTL. These include:
1) Reduction in the amount of tumour-derived immunosuppressive factors: Tumours secrete cytokines which are potential inhibitors of T-cell activation (e.g., IL-10 and TGFp") and of dendritic cell (DC) differentiation and maturation (IL-10, TGFP, IL-6, and VEGF) [19] [20] [21] [22] . Destruction of tumour cells by chemotherapy will reduce the production of those cytokines and favour the induction of tumour-specific CTL responses.
2) Improved recruitment and maturation of DC by GM-CSF: Deficient DC differentiation and functioning has recently been reported in patients with advanced breast cancer [23] . The treatment with GM-CSF may not only induce DC precursor mobilisation from the bone marrow, but may also improve DC maturation and activation, thus increasing the efficiency of tumour antigen presentation and the subsequent activation of tumour-specific CTL [24] .
3) GM-CSF mediated recruitment of DC to the tumour site: enhanced survival of tumour infiltrating lymphocytes (TIL): GM-CSF treatment may result in an increased number of DC infiltrating the primary tumour site. Previous studies have shown a better prognosis for patients with an increased number of tumour infiltrating DC [25] . This phenomenon may be explained by a DC-mediated protection of TIL from so-called tumour induced cell death. Tumour cells expressing Fas-ligand can induce Fas mediated apoptosis in T cells [26] [27] [28] [29] . DC have been reported to protect these cells from this premature programmed cell death by B7/CD28 [30, 31] interactions or possibly by the production of IL-12 [32, 33] .
4) Tumour cell apoptosis and DC-dependent crosspriming of CTL: DC can efficiently endocytose apoptotic cell fragments and present epitopes derived from these antigen-containing apoptotic bodies to CTL [34] . A re-cent report showed this process to be mediated by a v pV integrins on the cell membrane of DC [35] . Chemotherapy-induced apoptosis of the tumour cells will considerably increase tumour antigen availability for capture by DC and may lead to priming of tumourspecific CTL.
5) Tumour-specific CTL priming in the tumour-draining lymph nodes: Lymph nodes constitute the natural meeting point of DC and circulating T cells and provide the optimal micro-environment in terms of stimulatory cytokines-and other (co-)stimulatory signals for the priming of T cells. Conserving the tumour-draining lymph nodes during the neoadjuvant chemotherapy and GM-CSF treatment may thus ensure optimal circumstances under which the tumour antigen loaded DC can encounter, bind, and prime tumour-specific CTL.
The prolonged presence of the draining lymph nodes in combination with the repeated tumour antigen release and DC recruitment and activation through the high number of treatment cycles (at least six) may account for the observed increase in survival in LABC. This concept certainly needs to be exploited in other locally advanced primary tumours. We have recently initiated extended neoadjuvant chemotherapy plus GM-CSF in locally advanced oesophageal cancer.
At present we are investigating immuno-stimulatory effects of GM-CSF in axillary lymph nodes of LABC patients and tumour specific CTL activity in peripheral blood, tumour draining lymph nodes and the primary tumour in relation to the number of therapy cycles. Preliminary results indeed show an increase in the number of dendritic cells in lymph nodes of patients treated with neoadjuvant chemotherapy and GM-CSF correlating to the duration of treatment. Also an increased number of DC was observed as compared to patients who did not receive pre-operative treatment or neoadjuvant chemotherapy without GM-CSF (S. Luykx, manuscript in preparation). These findings support our first hypothesis.
Anti-angiogenetic properties of the primary tumour
Our second hypothesis refers to the generation of antiangiogenic peptides by the primary tumour that may keep micrometastases dormant.
The formation of new vessels from the pre-existing vasculature (angiogenesis) is required for primary tumour growth and its metastases. The switch from a prevascular to a vascular phenotype is tightly controlled by pro-and anti-angiogenic factors. In case, the balance is in favour of pro-angiogenic factors, new vessel formation will be turned on, while angiogenesis inhibitors keep tumours dormant under the reciprocal circumstance [36] . In dormant (prevascular) metastases the apoptotic rate of tumour cells is highly elevated compared to growing tumours, while the rate of proliferation is equal for both. Such a regulation of the tumour growth has been demonstrated in preclinical models and was recently described in patients with metastases from melanomas [37, 38] .
Many different cell types may influence the angiogenic balance in a tumour, including fibroblasts, macrophages, endothelial cells and supposedly platelets [36, [39] [40] [41] .
In accordance to the Lewis Lung carcinoma (LLC) model, patients with large primary tumours may lack clinically detectable distant metastases [42] . However, it is well known that similar to the LLC model, micrometastases are usually present in patients with LABC. In the LLC model a circulating inhibitor of angiogenesis, generated by the primary tumour, was identified (named angiostatin) and shown to be responsible for dormancy of micrometastases. Within three days after removal of the primary tumour, distant metastases started to grow rapidly.
In breast cancer patients circulating angiogenic and anti-angiogenic factors have been identified [41, 43, 44] . Recently, Morelli et al. described systemic pro-or antiangiogenic effects from the circulating blood of breast cancer patients. Serum from some patients clearly stimulated endothelial cell proliferation in vitro, whereas others were inhibitory. This inhibition could be blocked with a specific antibody against thrombospondin, indicative for its role [43] . One may anticipate that this finding is not unique for breast cancer. Presumably the primary tumour is responsible for the release of anti-angiogenic factors into the circulation. However, the exact source of these inhibitors is not defined yet. Interestingly, like angiostatin, which contains the first four kringles of plasminogen, many fragments of larger extracellular matrix (ECM) and plasma proteins have been shown to inhibit angiogenesis. These include fragments of fibronectin, prolactin, thrombospondin, collagen" XVIII and prothrombin and may all be generated during tissue remodelling [45] [46] [47] [48] [49] .
For angiostatin, it was demonstrated that a macrophage-derived metalloelastase, urokinase and membrane metallo proteinase-3 (MMP-3, expressed by macrophages) may be responsible for the production of angiostatin [50] [51] [52] . Furthermore, it has been reported that transfection of LLC cells with GM-CSF inhibited tumour growth, while an increased number of intratumoural macrophages and elevated concentrations of angiostatin in the serum as determined by Western blotting were measured [53] . These studies suggest a role for GM-CSF in the generation of a circulating angiogenesis inhibitor. Other anti-angiogenic fragments of larger proteins may be generated in a similar way.
As described in an earlier study [54] , we observed an increase in macrophages in the mastectomy specimens compared with the pre-treatment biopsies, possibly due to the administration of GM-CSF. In accordance to the LLC model, these macrophages may be responsible for the generation of angiostatin or other protein fragments inhibitory for angiogenesis.
Our second hypothesis (see Figure 2) is based on the presence of the primary tumour during treatment, which may contribute to the clinical results by release of anti- 
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Inhibition of angiogenesis at remote sites (synergism with chemotherapy) Figure 2 . Hypothesis: antiangiogenic properties of primary tumour stroma. During tumour growth and chemotherapy, fragments of larger proteins are generated and released into the circulation due to breakdown of the ECM (tissue remodelling). These fragments will inhibit angiogenesis in micrometastases and synergise with applied chemotherapy.
angiogenic factors into the circulation, in particular if the site of production is the stroma (e.g., infiltrated macrophages). These anti-angiogenic factors will keep micrometastases dormant and may synergise with the chemotherapy. Although the primary tumour often disappears prior to the end of systemic treatment, an inflammatory reaction remains at the original site of the tumour. Tissue remodelling, like in tumour growth, will cause degradation of the extracellular matrix by proteases and enzymatic cleavage of extracellular and plasma proteins. The fragments derived from these proteins may include angiostatin. When such fragments come into the circulation, they will cause inhibition of metastatic growth and synergise with the chemotherapy which is being continued.
Currently, plasma and serum of patients with locally advanced tumours are investigated for their effect on endothelial cell proliferation and searched for the presence of angiogenesis inhibitory (fragments of) ECM proteins.
Obviously our two hypotheses cannot be viewed entirely separately. A clear overlap between the immunomodulating and anti-angiogenic effects of the treatment approach in patients with locally advanced cancer exists. Pro-angiogenic factors (VEGF) have been shown to inhibit functional maturation of dendritic cells in vitro and recently in vivo [19, 20] . Presumably, inhibitors of angiogenesis will block this effect. In fact, adhesion molecules, important for leukocyte-endothelial interactions, are down regulated by pro-angiogenic factors, while expression is reinduced by inhibitors of angiogenesis such as thrombospondin and platelet factor-4 [55] .
Conclusion
Extended neoadjuvant chemotherapy with GM-CSF appears to show favourable results in patients with LABC. This effect was most apparent in patients who received six treatment cycles, implying that the primary tumour and draining axillary lymph nodes remained in situ for a prolonged period of time. In fact these lymph nodes might prove to be an essential 'life line' during treatment of these poor risk patients. Based on our findings and those from recent preclinical studies we hypothesise that treatment results of (locally advanced) primary cancers may improve by extended neoadjuvant systemic therapy taking advantage of biological processes in the primary tumour and its draining lymph nodes. We are presently studying these biological phenomena in tissue samples and have initiated a large international study, the Spinoza trial, in the Netherlands, Mexico, France and Spain, comparing the conventional approach of applying three preoperative and three postoperative cycles of chemoimmunotherapy, and the extended chemoimmunotherapy approach. Because of its new concept the study is attracting a great interest from the international scientific society. Indeed, considering our promising results it is definitely time to evaluate the role of maintaining the primary tumour plus draining lymph nodes for a prolonged period of time to support the systemic therapy in patients with high risk locally advanced tumours. Supposedly any biological process which is aimed to triggered by systemic treatment will take more than two months to gather momentum.
